Caribou Biosciences, Inc. (CRBU) is facing downward pressure today following the announcement of a class action securities lawsuit filed against the company. The lawsuit, filed by Levi & Korsinsky, LLP, alleges that Caribou Biosciences made false statements regarding the safety, efficacy, and commercial prospects of its CB-010 therapy. The complaint also claims that the company was at risk of insufficient capital to fund its operations, which could have a significant negative impact on its business. Investors affected by these alleged misrepresentations have until February 24, 2025, to request to be appointed as lead plaintiff in the case.
The stock is currently trading at $1.64, down 4.94% from the previous close of $1.72. It opened at $1.72 and has seen a low of $1.63 so far today. Despite being just 30 minutes into the trading day, the stock has already seen a volume of 328,365 shares, which is 22.08% of its average daily volume of 1,487,422 shares.